48° and Overcast
Image
The gene-based treatments include medications Lyfgenia, the first that uses the gene-editing technique CRISPR, and Casgevy.
An estimated 1 of every 365 Black babies born in the US have sickle cell. Patients aged 12 and older with histories of vaso-occlusive crises potentially qualify for this new treatment.
Medical researchers will follow patients who receive Casgevy or Lyfgenia in a long-term study to evaluate each product’s safety and effectiveness. More information is here.
https://health.allwomenstalk.com/the-health-benefits-of-crispr/
